| Study of Immunotherapy to Treat Advanced Prostate Cancer
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III | Treatment | Approved-not yet active | 18 and over | CA184-043
2008-003314-97, NCT00861614 |
Trial Description
Summary The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone Eligibility Criteria Inclusion Criteria: - At least 1 bone metastasis
- Prior treatment with docetaxel
Exclusion Criteria: - Known HIV, Hep B, or Hep C infection
- More than 2 prior systemic anticancer regimens for prostate cancer
- Prior treatment on BMS CA180227 for prostate cancer
Trial Contact Information
Trial Lead Organizations/Sponsors Bristol-Myers Squibb Company - New York | Bristol-Myers Squibb |  | Study Director |
| For participation information at a USA site use a phone number below. For site information outside the USA please email: | | | | |
Email:
Clinical.Trials@bms.com |
| First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time. | | |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00861614
Information obtained from ClinicalTrials.gov on May 07, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
